Brainsway (BWAY) has released an update.
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health, has been approved by the Israel Ministry of Defense for PTSD treatment reimbursement at Israeli hospitals. This marks a significant advancement in addressing PTSD, which has become a growing concern in Israel, especially after recent conflicts. The company is actively working to expand this reimbursement to more medical centers and private clinics, bolstering its commitment to improving mental health care with its Deep TMS technology.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
